Page 97 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine Nanomaterials in cancer chemoimmunotherapy

platforms for cancer immunotherapy. Wiley Interdiscip Rev from sipuleucel-T: New dendritic cell vaccine strategies for
Nanomed Nanobiotechnol. 2019;12:e1590. prostate cancer. Front Immunol. 2021;12:641307.
doi: 10.1002/wnan.1590 doi: 10.3389/fimmu.2021.641307
3. Bockamp E, Rosigkeit S, Siegl D, Schuppan D. Nano- 14. Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene
enhanced cancer immunotherapy: Immunology encounters laherparepvec (T-VEC): An intralesional cancer
nanotechnology. Cells. 2020;9:2102. immunotherapy for advanced melanoma. Cancers (Basel).
2021;13(6):1383.
doi: 10.3390/cells9092102
doi: 10.3390/cancers13061383
4. Zhang P, Meng J, Li Y, et al. Nanotechnology-enhanced
immunotherapy for metastatic cancer. Innovation (Camb). 15. Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy
2021;2(4):100174. for cancer treatment. Exploration (Beijing). 2023;3:20210058.
doi: 10.1016/j.xinn.2021.100174 doi: 10.1002/EXP.20210058
5. Wang J, Li L, Xu ZP. Enhancing cancer chemo- 16. Lasvergnas J, Naigeon M, Chouahnia K, Zelek L, Chaput N,
immunotherapy: Innovative approaches for overcoming Duchemann B. Adoptive cell therapies in thoracic
immunosuppression by functional nanomaterials. Small malignancies. Cancer Immunol Immunother. 2022;71:2077-
Methods. 2024;8:e2301005. 2098.
doi: 10.1002/smtd.202301005 doi: 10.1007/s00262-022-03142-3
6. Akkın S, Varan G, Bilensoy E. A review on cancer 17. Robert C, Soria JC, Eggermont AMM. Drug of the year:
immunotherapy and applications of nanotechnology to Programmed death-1 receptor/programmed death-1
chemoimmunotherapy of different cancers. Molecules. ligand-1 receptor monoclonal antibodies. Eur J Cancer.
2021;26:3382. 2013;49:2968-2971.
doi: 10.3390/molecules26113382 doi: 10.1016/j.ejca.2013.07.001
7. Lang X, Wang X, Han M, Guo Y. Nanoparticle-Mediated 18. Dhillon S. Trastuzumab emtansine: A review of its use
synergistic chemoimmunotherapy for cancer treatment. Int in patients with HER2-positive advanced breast cancer
J Nanomedicine. 2024;19:4533-4568. previously treated with trastuzumab-based therapy. Drugs.
2014;74:675-686.
doi: 10.2147/IJN.S455213
doi: 10.1007/s40265-014-0201-0
8. Bagherifar R, Kiaie SH, Hatami Z, et al. Nanoparticle-
mediated synergistic chemoimmunotherapy for tailoring 19. Lin FC, Young HA. Interferons: Success in anti-viral
cancer therapy: Recent advances and perspectives. immunotherapy. Cytokine Growth Factor Rev. 2014;25:369-376.
J Nanobiotechnology. 2021;19:110.
doi: 10.1016/j.cytogfr.2014.07.015
doi: 10.1186/s12951-021-00861-0
20. Murer P, Brannetti B, Rondeau JM, et al. Discovery and
9. Mu W, Chu Q, Liu Y, Zhang N. A review on nano-based development of ANV419, an IL-2/anti-IL-2 antibody
drug delivery system for cancer chemoimmunotherapy. fusion protein with potent CD8+ T and natural killer cell-
Nanomicro Lett. 2020;12:142. stimulating capacity for cancer immunotherapy. MAbs.
2024;16:2381891.
doi: 10.1007/s40820-020-00482-6
doi: 10.1080/19420862.2024.2381891
10. Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: An
alternative promising therapeutic approach against cancers. 21. Emens LA. Chemoimmunotherapy: Reengineering tumor
Mol Biol Rep. 2022;49:9903-9913. immunity. J Cancer. 2010;16:295-303.
doi: 10.1007/s11033-022-07525-8 doi: 10.1007/s00262-012-1388-0
11. Stanley M. Tumour virus vaccines: Hepatitis B virus and 22. Wang T, Suita Y, Miriyala S, Dean J, Tapinos N, Shen J.
human papillomavirus. Philos Trans R Soc Lond B Biol Sci. Advances in lipid-based nanoparticles for cancer
2017;372:20160268. chemoimmunotherapy. Pharmaceutics. 2021;13(4):520.
doi: 10.1098/rstb.2016.0268 doi: 10.3390/pharmaceutics13040520
12. Kamolratanakul S, Pitisuttithum P. Human papillomavirus 23. You K, Wang Q, Osman MS, et al. Advanced strategies
vaccine efficacy and effectiveness against cancer. Vaccines for combinational immunotherapy of cancer based on
(Basel). 2021;9(12):1413. polymeric nanomedicines. BMEMat. 2024;2:e12067.
doi: 10.3390/vaccines9121413 doi: 10.1002/bmm2.12067
13. Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on 24. Liu S, Li J, Gu L, Wu K, Xing H. Nanoparticles for

Volume 3 Issue 1 (2025) 89 doi: 10.36922/arnm.8150